Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04115059 · OUTCOME

Time to Next Therapy (TTNT)

Dasatinib In Waldenström Macroglobulinemia · Source last updated 2024-03-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
From first dose through initiation of new therapy, up to 2 years from baseline

What was measured

The amount of time between starting study treatment and initiating a new therapy

Groups in this outcome

Dasatinib

\-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle. Dasatinib: Oral Study Drug(s): * Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day. * This will continue for up to 24 cycles. Dasatinib: Oral, daily, dosing per protocol, once a day for cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dasatinib3

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Dasatinib6Not reported16Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        6
        value
        6
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    units
    Participants
description
The amount of time between starting study treatment and initiating a new therapy
dispersion Type
Full Range
groups
  1. description
    \-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle. Dasatinib: Oral Study Drug(s): * Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day. * This will continue for up to 24 cycles. Dasatinib: Oral, daily, dosing per protocol, once a day for cycle
    id
    OG000
    title
    Dasatinib
param Type
MEDIAN
reporting Status
POSTED
time Frame
From first dose through initiation of new therapy, up to 2 years from baseline
title
Time to Next Therapy (TTNT)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice